Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans

Cardiovascular Pathology

Volumn 22, Issue 2, 2013, Pages 146-155

  Osman, Narin ^a,b   Grande Allen, K Jane ^c   Ballinger, Mandy L ^d   Getachew, Robel ^a   Marasco, Silvana ^e   O'Brien, Kevin D ^f   Little, Peter J ^a,b  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Rice University   (United States)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Glycosaminoglycans; Heart valves; Lipids; Smad; Transforming growth factor

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALPHA SMOOTH MUSCLE ACTIN; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOGLYCAN; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; SULFUR 35; TRANSFORMING GROWTH FACTOR BETA1;

AORTA VALVE; AORTA VALVE DISEASE; AORTIC VALVE INTERSTITIAL CELL; ARTICLE; CALCIFIC AORTIC VALVE DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOGLYCAN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; AORTIC VALVE; BENZAMIDES; CELLS, CULTURED; DIOXOLES; GLYCOSAMINOGLYCANS; HEART VALVE DISEASES; HUMANS; LIPOPROTEINS, LDL; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SWINE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84873410033     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2012.07.002     Document Type: Article

References (60)

1. C.M. Otto, I.G. Burwash, M.E. Legget, B.I. Munt, M. Fujioka, and N.L. Healy Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome Circulation 95 9 1997 2262 2270
2. C.M. Otto, B.K. Lind, D.W. Kitzman, B.J. Gersh, and D.S. Siscovick Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly N Engl J Med 341 3 1999 142 147
3. P.G. Supino, J.S. Borer, J. Preibisz, and A. Bornstein The epidemiology of valvular heart disease: a growing public health problem Heart Fail Clin 2 4 2006 379 393
4. W.C. Roberts, and J.M. Ko Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation Circulation 111 7 2005 920 925
5. K.D. O'Brien Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more) Arterioscler Thromb Vasc Biol 26 8 2006 1721 1728
6. K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res 76 1 2007 19 28
7. C.M. Otto, J. Kuusisto, D.D. Reichenbach, A.M. Gown, and K.D. O'Brien Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 2 1994 844 853
8. K.D. O'Brien, K.L. Olin, C.E. Alpers, W. Chiu, M. Ferguson, and K. Hudkins Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins Circulation 98 6 1998 519 527
9. E.R. Mohler Mechanisms of aortic valve calcification Am J Cardiol 94 11 2004 396 1402 A1396
10. N.M. Rajamannan Calcific aortic stenosis. Lessons learned from experimental and clinical studies Arterioscler Thromb Vasc Biol 2008
11. W.S. Aronow, C. Ahn, I. Kronzon, and M.E. Goldman Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons Am J Cardiol 88 6 2001 693 695
12. P. Raggi, J. Bommer, and G.M. Chertow Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer J Heart Valve Dis 13 1 2004 134 141
13. B.F. Stewart, D. Siscovick, B.K. Lind, J.M. Gardin, J.S. Gottdiener, and V.E. Smith Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 3 1997 630 634
14. M. Lindroos, M. Kupari, J. Heikkila, and R. Tilvis Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample J Am Coll Cardiol 21 5 1993 1220 1225
15. N.M. Rajamannan, M. Subramaniam, M. Springett, T.C. Sebo, M. Niekrasz, and J.P. McConnell Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve Circulation 105 22 2002 2660 2665
16. B. Wu, S. Elmariah, F.S. Kaplan, G. Cheng, and E.R. Mohler Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease Arterioscler Thromb Vasc Biol 25 3 2005 592 597
17. K. Pohle, R. Maffert, D. Ropers, W. Moshage, N. Stilianakis, and W.G. Daniel Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors Circulation 104 16 2001 1927 1932
18. D.M. Shavelle, J. Takasu, M.J. Budoff, S. Mao, X.Q. Zhao, and K.D. O'Brien HMG CoA reductase inhibitor (statin) and aortic valve calcium Lancet 359 9312 2002 1125 1126
19. K.D. O'Brien, J.L. Probstfield, M.T. Caulfield, K. Nasir, J. Takasu, and D.M. Shavelle Angiotensin-converting enzyme inhibitors and change in aortic valve calcium Arch Intern Med 165 8 2005 858 862
20. R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, and U. Klaar Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis Circulation 110 10 2004 1291 1295
21. K.D. O'Brien, D.M. Shavelle, M.T. Caulfield, T.O. McDonald, K. Olin-Lewis, and C.M. Otto Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma Circulation 106 17 2002 2224 2230
22. S. Helske, K.A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, and J. Lommi Induction of local angiotensin II-producing systems in stenotic aortic valves J Am Coll Cardiol 44 9 2004 1859 1866
23. S.J. Cowell, D.E. Newby, R.J. Prescott, P. Bloomfield, J. Reid, and D.B. Northridge A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis N Engl J Med 352 23 2005 2389 2397
24. A.B. Rossebo, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, and K. Egstrup Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 13 2008 1343 1356
25. K.L. Chan, K. Teo, J.G. Dumesnil, A. Ni, and J. Tam Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial Circulation 121 2 2010 306 314
26. E. Aikawa, M. Nahrendorf, J.L. Figueiredo, F.K. Swirski, T. Shtatland, and R.H. Kohler Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo Circulation 116 24 2007 2841 2850
27. M. Cimini, D.R. Boughner, J.A. Ronald, L. Aldington, and K.A. Rogers Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study J Heart Valve Dis 14 3 2005 365 375
28. K.D. O'Brien, C.M. Otto, D.D. Reichenbach, C.E. Alpers, and T.W. Wight Regional accumulation of proteoglycans in lesions of "degenerative" valvular aortic stenosis and their relationship to apolipoproteins Circulation 92 8 (Suppl 1) 1995 612
29. E.H. Stephens, J.G. Saltarrelli, L.S. Baggett, I. Nandi, J.J. Kuo, and A.R. Davis Differential proteoglycan and hyaluronan distribution in calcified aortic valves Cardiovasc Pathol 2010
30. K.D. O'Brien, D.D. Reichenbach, S.M. Marcovina, J. Kuusisto, C.E. Alpers, and C.M. Otto Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis Arterioscler Thromb Vasc Biol 16 4 1996 523 532
31. J.H. Chen, and C.A. Simmons Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues Circ Res 108 12 2011 1510 1524
32. B. Jian, N. Narula, Q.Y. Li, E.R. Mohler, and R.J. Levy Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis Ann Thorac Surg 75 2 2003 457 465
33. E. Schonherr, H.T. Jarvelainen, M.G. Kinsella, L.J. Sandell, and T.N. Wight Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells Arterioscler Thromb 13 7 1993 1026 1036
34. P.J. Little, L. Tannock, K.L. Olin, A. Chait, and T.N. Wight Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs Arterioscler Thromb Vasc Biol 22 1 2002 55 60
35. M.L. Ballinger, J. Nigro, K.V. Frontanilla, A.M. Dart, and P.J. Little Regulation of glycosaminoglycan structure and atherogenesis Cell Mol Life Sci 61 11 2004 1296 1306
36. K.J. Williams, and I. Tabas The response-to-retention hypothesis of early atherogenesis Arterioscler Thromb Vasc Biol 15 5 1995 551 561
37. T.L. Blevins, J.L. Carroll, A.M. Raza, and K.J. Grande-Allen Phenotypic characterization of isolated valvular interstitial cell subpopulations J Heart Valve Dis 15 6 2006 815 822
38. J. Nigro, R.J. Dilley, and P.J. Little Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells Atherosclerosis 162 1 2002 119 129
39. L.R. Tannock, P.J. Little, C. Tsoi, P.H.R. Barrett, T.N. Wight, and A. Chait Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans Diabetologia 47 5 2004 837 843
40. J. Nigro, M. Ballinger, R. Dilley, G. Jennings, T. Wight, and P. Little Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding Diabetologia 47 2004 2105 2113
41. J.W. Heinecke, L. Baker, H. Rosen, and A. Chait Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells J Clin Invest 77 3 1986 757 761
42. P.M. Taylor, P. Batten, N.J. Brand, P.S. Thomas, and M.H. Yacoub The cardiac valve interstitial cell Int J Biochem Cell Biol 35 2 2003 113 118
43. E. Rabkin-Aikawa, M. Farber, M. Aikawa, and F.J. Schoen Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves J Heart Valve Dis 13 5 2004 841 847
44. N.M. Rajamannan, F.J. Evans, E. Aikawa, K.J. Grande-Allen, L.L. Demer, and D.D. Heistad Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group* executive summary: calcific aortic valve disease - 2011 update Circulation 124 16 2011 1783 1791
45. S. Gao, C. Alarcon, G. Sapkota, S. Rahman, P.Y. Chen, and N. Goerner Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling Mol Cell 36 3 2009 457 468
46. J. Yue, R.S. Frey, and K.M. Mulder Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta Oncogene 18 11 1999 2033 2037
47. J.H. Chen, W.L. Chen, K.L. Sider, C.Y. Yip, and C.A. Simmons beta-catenin mediates mechanically regulated, transforming growth factor-beta1-induced myofibroblast differentiation of aortic valve interstitial cells Arterioscler Thromb Vasc Biol 31 3 2011 590 597
48. F. Blanchette, N. Rivard, P. Rudd, F. Grondin, L. Attisano, and C.M. Dubois Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation J Biol Chem 276 36 2001 33986 33994
49. M.L. Burch, S.N. Yang, M.L. Ballinger, R. Getachew, N. Osman, and P.J. Little TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2 Cell Mol Life Sci 67 12 2010 2077 2090
50. R.F. Ankeny, V.H. Thourani, D. Weiss, J.D. Vega, W.R. Taylor, and R.M. Nerem Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves - association with low BMP antagonists and SMAD6 PLoS One 6 6 2011 e20969
51. C. Alarcon, A.I. Zaromytidou, Q. Xi, S. Gao, J. Yu, and S. Fujisawa Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways Cell 139 4 2009 757 769
52. H. Derbali, Y. Bosse, N. Cote, P. Pibarot, A. Audet, and A. Pepin Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2 Am J Pathol 176 6 2010 2638 2645
53. A. Parolari, E. Tremoli, L. Cavallotti, M. Trezzi, S. Kassem, and C. Loardi Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 97 7 2011 523 529
54. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 16 2007 1832 1844
55. Y. Nakashima, H. Fujii, S. Sumiyoshi, T.N. Wight, and K. Sueishi Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration Arterioscler Thromb Vasc Biol 27 5 2007 1159 1165
56. M.K. Lee, C. Pardoux, M.C. Hall, P.S. Lee, D. Warburton, and J. Qing TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA EMBO J 26 17 2007 3957 3967
57. H. Ungefroren, S. Groth, M. Ruhnke, H. Kalthoff, and F. Fandrich Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta J Biol Chem 280 4 2005 2644 2652
58. H. Dadlani, M.L. Ballinger, N. Osman, R. Getachew, and P.J. Little Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle J Biol Chem 283 12 2008 7844 7852
59. S.W. Rabkin, P. Lodhia, and M.W. Luong P38 MAP kinase in valve interstitial cells is activated by angiotensin II or nitric oxide/peroxynitrite, but reduced by Toll-like receptor-2 stimulation J Heart Valve Dis 18 6 2009 653 661
60. X. Gu, and K.S. Masters Role of the MAPK/ERK pathway in valvular interstitial cell calcification Am J Physiol Heart Circ Physiol 296 6 2009 H1748 H1757